AHRP PROPOSAL:
Any FDA-approved drug, whose manufacturer has been found by a court of law or the Department of Justice–to have illegally marketed the drug by concealing risks or incidence of adverse effects, or making unsupported claims of clinical benefit–should be denied coverage by taxpayer funded insurance programs–including Medicaid, Medicare, VeteranstAffairs.

Read More

"Anything you put in that book, any little change you make, has huge implications not only for psychiatry but for pharmaceutical marketing, research, for the legal system, for who’s considered to be normal or not, for who’s considered disabled," said Dr. Michael First, professor of psychiatry at Columbia University who edited the DSM4l but is not involved in the DSM5.

Read More

In December, 2009, Bloomberg News published an investigative report by David Evans reported, "Big Pharma’s Crime Spree"   documenting major court settlements: "Pfizer, Eli Lilly & Co., Bristol-Myers Squibb Co. and four other drug companies have paid a total of $7 billion in fines and penalties. Six of the companies admitted in court that they…

Read More

Sen. Grassley obtained documents confirming NAMI as a front group for pharma companies who underwrite ¾ of NAMI donations—in 2006 to 2008 that was a hefty $23 million.

Read More

“I was trained from day one to market the drug illegally…My job was to promote Neurontin and motivate doctors to experiment on patients. After being hired as a medical liaison, I was selling drugs. The uses promoted were from the “snake-oil list” of 13 medical conditions."  

Read More

The study, reported in The Journal of the American Medical Association, "found no evidence of an association between the serotonin gene and the risk of depression, no matter what people’s life experience was."

Read More